...
首页> 外文期刊>Journal of Clinical Oncology >Association Between Inflammatory Biomarker C-Reactive Protein and Radiotherapy-Induced Early Adverse Skin Reactions in a Multiracial/Ethnic Breast Cancer Population
【24h】

Association Between Inflammatory Biomarker C-Reactive Protein and Radiotherapy-Induced Early Adverse Skin Reactions in a Multiracial/Ethnic Breast Cancer Population

机译:炎症生物标志物C反应蛋白与放射治疗诱导的多种族/民族乳腺癌人口的早期不良皮肤反应的关系

获取原文
获取原文并翻译 | 示例
           

摘要

PurposeThis study examined an inflammatory biomarker, high-sensitivity C-reactive protein (hsCRP), in radiotherapy (RT)-induced early adverse skin reactions or toxicities in breast cancer.Patients and MethodsBetween 2011 and 2013, 1,000 patients with breast cancer who underwent RT were evaluated prospectively for skin toxicities through the National Cancer Institute-funded Wake Forest University Community Clinical Oncology Program Research Base. Pre- and post-RT plasma hsCRP levels and Oncology Nursing Society skin toxicity criteria (0 to 6) were used to assess RT-induced skin toxicities. Multivariable logistic regression analyses were applied to ascertain the associations between hsCRP and RT-induced skin toxicities after adjusting for potential confounders.ResultsThe study comprised 623 white, 280 African American, 64 Asian/Pacific Islander, and 33 other race patients; 24% of the patients were Hispanic, and 47% were obese. Approximately 42% and 15% of patients developed RT-induced grade 3+ and 4+ skin toxicities, respectively. The hsCRP levels differed significantly by race and body mass index but not by ethnicity. In multivariable analysis, grade 4+ skin toxicity was significantly associated with obesity (odds ratio [OR], 2.17; 95% CI, 1.41 to 3.34], post-RT hsCRP 4.11 mg/L (OR, 1.61; 95% CI, 1.07 to 2.44), and both factors combined (OR, 3.65; 95% CI, 2.18 to 6.14). Above-median post-RT hsCRP (OR, 1.93; 95% CI, 1.03 to 3.63), and change in hsCRP (OR, 2.80; 95% CI, 1.42 to 5.54) were significantly associated with grade 4+ skin toxicity in nonobese patients.ConclusionThis large prospective study is the first to our knowledge of hsCRP as an inflammatory biomarker in RT-induced skin toxicities in breast cancer. We demonstrate that nonobese patients with elevated RT-related change in hsCRP levels have a significantly increased risk of grade 4+ skin toxicity. The outcomes may help to predict RT responses and guide decision making.
机译:目的研究检测炎症生物标志物,高敏感性C反应蛋白(HSCRP),放射治疗(RT)诱导乳腺癌早期不良皮肤反应或毒性。2011年和2013年的患者和方法,1,000名患有RT的乳腺癌患者通过全国癌症学院资助的森林大学社区临床肿瘤肿瘤学计划研究基地,对皮肤毒性进行了评估。在RT后和后血浆HSCRP水平和肿瘤学院护理社会皮肤毒性标准(0至6)用于评估RT诱导的皮肤毒性。应用多变量的逻辑回归分析来确定潜在混淆后HSCRP和RT诱导的皮肤毒性的关联。研究包括623名白色,280名非洲裔美国,64名亚洲/太平洋岛屿和33名其他种族患者; 24%的患者是西班牙裔,47%的人肥胖。大约42%和15%的患者分别产生RT诱导的3 +和4+皮肤毒性。种族和体重指数但不受种族的竞赛和体重指数显着不同。在多变量分析中,4级以上的皮肤毒性与肥胖症显着相关(差距比[或],2.17; 95%CI,1.41至3.34],RT HSCRP 4.11mg / L(或1.61; 95%CI,1.07至2.44),两种因素组合(或3.65; 95%CI,2.18至6.14)。中位于RT HSCRP后的中位数(或1.93; 95%CI,1.03至3.63),以及HSCRP的变化(或, 2.80; 95%CI,1.42至5.54)与非同一患者的4级皮肤毒性显着相关。结论大型前瞻性研究是我们在乳腺癌中的RT诱导皮肤毒性中作为炎症生物标志物的首次知识。我们证明HSCRP水平RT相关变化的非与RT相关变化的患者具有显着增加的4级皮肤毒性风险。结果可能有助于预测RT响应和指导决策。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号